// Area 03 — Therapeutics
A molecule that
survives the route.
Protein and biologic therapeutics — engineering for stability, expression and manufacturability, so a molecule that works at the bench survives the route to a clinical batch.
- Modality
- Proteins & biologics
- We engineer
- Stability, expression, developability
- Constraint
- Manufacturability from day one
- Partners
- CROs & contract manufacturers
// Therapeutics
Developability is a design input.
Treating manufacture as a later problem is what kills good molecules.
A biologic that works in a flask and cannot be expressed at scale, or aggregates on storage, or loses activity through a purification train, is not a candidate. It is a result.
Developability constraints belong in the design, not in a review afterwards. We engineer for them from the start: expression host and construct strategy, thermal and colloidal stability, aggregation propensity, and the behaviour of the molecule through the steps it will actually go through.
Where we come in
- Sequence and structure-level engineering for stability and expression.
- Developability assessment in silico before committing laboratory time.
- Construct design — formats, linkers, tags and the variants worth testing.
- Aggregation and formulation behaviour under realistic conditions.
- Working with the CROs and manufacturers who take the molecule forward.
Why in silico first
Because the expensive part is making and testing. Ranking candidates for affinity, stability, expression and developability before synthesis means the bench work starts from a shortlist that is already plausible, and each design–build–test cycle starts better informed than the last.
// Capability
What we
actually do.
The specific pieces of work an engagement in this area is made of.
- 01
Developability triage
In-silico assessment of stability, aggregation and expression risk before synthesis.
- 02
Stability engineering
Sequence and structural changes that hold activity through storage and handling.
- 03
Expression strategy
Host, construct and format decisions that make a useful yield achievable.
- 04
Format & construct design
Linkers, fusions, tags and the variant set worth putting through the bench.
- 05
Manufacturability review
Checking the molecule against the process it will actually be made by.
- 06
Partner handover
Working alongside CROs and contract manufacturers who take it to a clinical batch.
// Questions
Asked
often.
If yours is not here, ask it directly — every enquiry is read by someone who can answer it.
Our molecule aggregates. Can that be engineered out?
Often, yes — aggregation usually traces to identifiable surface patches or a stability deficit. Whether it can be fixed without losing activity is the real question, and it is answerable computationally before you spend on synthesis.
Do you manufacture?
No. We design and engineer, and we work with the CROs and contract manufacturers who produce. Part of our support programme is sourcing and managing those relationships.
Can you improve expression without changing the binding site?
That is usually the brief. Most of the levers for expression and stability sit away from the functional surface.